NASDAQ:BPTH
Bio-Path Holdings Stock News
$2.61
-0.0500 (-1.88%)
At Close: May 03, 2024
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (Nasdaq: BPTH)
02:25pm, Friday, 06'th Dec 2019
DALLAS, TX / ACCESSWIRE / December 6, 2019 / Bio-Path Holdings, Inc. (NASDAQ:BPTH). The full report can be accessed by clicking on the following link: http://stonegateinc.com/reports/BPTH%20DEC%202019
Edited Transcript of BPTH earnings conference call or presentation 15-Nov-19 1:30pm GMT
02:42am, Friday, 06'th Dec 2019
Q3 2019 Bio Path Holdings Inc Earnings Call
Bio-Path (BPTH) Upgraded to Buy: Here's What You Should Know
05:00pm, Wednesday, 04'th Dec 2019
Bio-Path (BPTH) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bio-Path (BPTH) Upgraded to Buy: Here's What You Should Know
12:00am, Wednesday, 04'th Dec 2019H.C. Wainwright Reiterates Buy on Bio-Path Holdings, Lowers Price Target to $25
12:00am, Monday, 02'nd Dec 2019Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia
01:00pm, Tuesday, 26'th Nov 2019
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, tod
Bio-Path Reports Successful Completion Of Safety Testing In Stage 2 Of Phase 2 Trial In Acute Myeloid Leukemia
12:00am, Tuesday, 26'th Nov 2019Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market
07:11pm, Monday, 25'th Nov 2019
Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, t
